Dong阳光 Pharma and XtalPi Holdings Announce Strategic Partnership to Establish AI-Driven Drug Discovery Joint Venture

Viewpoint News:January 26, GuangdongDongyang LightDongyangguang Pharmaceutical Co., Ltd. and XtalPi Holdings Limited Formally Establish Strategic Cooperation. Dongyangguang Pharmaceutical is Expected to Invest Hundreds of Millions, and the Two Parties Will Jointly Establish a Joint Venture Aiming to Build an Industry-Leading AI Drug R&D Engine, Promote Technology Overseas, and Construct a Diversified Profit Model of "Pipeline Co-Creation + Technical Win-Win."

Dongyang Guangya Pharmaceutical is a leading pharmaceutical enterprise in China with over 150 approved drugs and more than 100 drugs in development, possessing real-world data assets. It has deep expertise in biological insights, drug discovery, and development; XtalPi, as a global leader in AI-driven drug discovery platforms, relies on quantum physics, artificial intelligence, and…RobotThe unique advantage of experimental fusion has formed a complete technical chain from virtual design to wet-lab validation.

Through this collaboration, Dongyang Guangya Pharmaceutical's real-world data assets are deeply integrated with XtalPi's innovative advantages of "quantum physics + AI + robotics." Both parties will focus on the field of autoimmune diseases, combining Dongyang Guangya Pharmaceutical's full-chain R&D experience with XtalPi's AI drug discovery technology to accelerate the discovery and clinical translation of candidate drugs. The two parties will also build an AI supercomputing platform based on the “computing power + data + ecosystem” model, opening up their collaborative achievements to academia and industry. This effort aims to transform data assets and AI products into the “Model as a Service” (MaaS) business model.

Disclaimer: The content and data in this article are organized by the author based on publicly available information, and do not constitute investment advice. Please verify before use.